Evidence map›Paper›PMID 33400293›Full record

ArticleThe British journal of dermatology2021

Modular gene analysis reveals distinct molecular signatures for subsets of patients with cutaneous lupus erythematosus.

J L Zhu, L T Tran, M Smith, F Zheng, L Cai, J A James, J M Guthridge, B F Chong

Open access · greenAbstract read
In one paragraph

Article in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Recent advances in cutaneous lupus.Journal of autoimmunity · 2022
    Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

J L ZhuDepartment of Dermatology, University of Texas at Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9823-964X
L T TranArthritis and Clinical Research Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.ORCID 0000-0002-1681-4231
M SmithArthritis and Clinical Research Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.ORCID 0000-0003-0651-809X
F ZhengArthritis and Clinical Research Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
L CaiDepartment of Population and Data Sciences, Quantitative Biomedical Research Center, Dallas, TX, USA.ORCID 0000-0002-9057-2998
J A JamesArthritis and Clinical Research Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.ORCID 0000-0002-9574-7355
J M GuthridgeArthritis and Clinical Research Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.ORCID 0000-0002-9308-237X
B F ChongDepartment of Dermatology, University of Texas at Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-4092-7658
Oklahoma Medical Research Foundation · USSouthwestern Medical CenterQuantitative BioSciences · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI Joel Marvin Guthridge · 2018 to 2026
$8.5M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
Molecular Markers in Discoid Lupus ErythematousK23AR061441 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHONG, BENJAMIN FRANKLIN · 2012 to 2016
$653k
NIAID NIH HHS UM1 AI144292NIAMS NIH HHS K23 AR061441NIAMS NIH HHS P30 AR073750NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

backgroundCutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune disease with clinical sequelae such as itching, dyspigmentation and scarring.

objectivesWe applied a previously described modular analysis approach to assess the molecular heterogeneity of patients with CLE.

methodsWhole-blood transcriptomes of RNA sequencing data from a racially and ethnically diverse group of patients with CLE (n = 62) were used to calculate gene co-expression module scores. An unsupervised cluster analysis and k-means clustering based on these module scores were then performed. We used Fisher's exact tests and Kruskal-Wallis tests to compare characteristics between patient clusters.

resultsSix unique clusters of patients with CLE were identified from the cluster analysis. We observed that seven inflammation modules were elevated in two clusters of patients with CLE. Additionally, these clusters were characterized by interferon, neutrophil and cell-death signatures, suggesting that interferon-related proteins, neutrophils and cell-death processes could be driving the inflammatory response in these subgroups. Three different clusters had a predominant T-cell signature, which were supported by lymphocyte counts.

conclusionsOur data support a diverse molecular profile in CLE that further adds to the clinical variations of this skin disease, and may affect disease course and treatment selection. Future studies with a larger and diverse cohort of patients with CLE are warranted to confirm these findings.

Indexed as

Lupus Erythematosus, CutaneousCicatrixCohort StudiesGenetic TestingHumans

Identifiers

PMID33400293
PMCPMC8255330
OpenAlexW3121011480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.